The European Union's medicines regulator said on Monday it will give region-wide recommendations for the COVID-19 antiviral pill jointly developed by Merck and Ridgeback Biotherapeutics in the "shortest possible" time-frame.
The European Medicines Agency (EMA) said it was reviewing the available data as the watchdog seeks to help member states before possible approval.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.